OOS Failures Addressed
This article was originally published in The Gold Sheet
Executive Summary
At a recent workshop on inspection trends at the recent PDA/FDA joint regulatory conference held in Washington on Sept. 24 FDA official Edwin Rivera noted that in terms of a firm's investigation of out-of-specification (OOS) test results, "the concern is that once you are in the Phase 2 investigation of the OOS failure the emphasis should be on the investigation and trying to determine the root cause. Often times what we see during our inspection is that the companies are pretty quick to do a re-test and a re-sample. We at FDA say in the OOS guidance that once you are in the Phase 2 a true OOS investigation should place more focus on the investigation and trying to find a root cause.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.